Dual target dilemma: navigating epcoritamab vs. glofitamab in relapsed refractory diffuse large B-cell lymphoma

Expert Rev Hematol. 2023 Jul-Dec;16(12):915-918. doi: 10.1080/17474086.2023.2285978. Epub 2023 Dec 18.

Authors

James A Davis¹, Katelynn Granger¹, Alex Sakowski¹, Sara Goodwin¹, Amanda Herbst¹, Deidra Smith¹, Lindsey Hendrickson¹, Victoria R Nachar²

Affiliations

¹ Department of Malignant Hematology and Bone Marrow Transplant, The Medical University of South Carolina Hollings Cancer Center, Charleston, SC, USA.
² Department of Pharmacy, University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA.

PMID: 37982732
DOI: 10.1080/17474086.2023.2285978

No abstract available

Keywords: CD20/CD3; DLBCL; bispecific antibodies; epcoritamab; glofitamab.

Publication types

Editorial

MeSH terms

Antibodies, Bispecific* / therapeutic use
Antineoplastic Agents* / therapeutic use
Humans
Lymphoma, Large B-Cell, Diffuse* / drug therapy
Lymphoma, Large B-Cell, Diffuse* / pathology
Lymphoma, Non-Hodgkin* / drug therapy

Substances

glofitamab
Antineoplastic Agents
Antibodies, Bispecific